The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

A new report from leading contract research organisation Novotech has shed light on the current state of play in the global cervical cancer clinical trial landscape. The report, which covers an ...

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75 ...

In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... The study was funded by the Merck Investigator ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...